The request for additional records delays the deal, and could indicate that the commission has specific concerns about the merger between the Botox vendor and an aesthetic device manufacturer.

The brokered deal will broaden DiaSorin’s offerings in the rapidly growing liquid diagnostics market, while also providing Luminex furthered access to markets outside of the US.

Pear has commercialized FDA-cleared prescription digital therapeutics for substance abuse disorder, opioid use disorder and chronic insomnia and has 14 more in development. CEO Corey McCann explained Pear’s vision for how PDTs can transform health care.